Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $57.80 | Total: $289.00 |
| 1 | 10 | $48.96 | Total: $489.60 |
| 1 | 25 | $41.48 | Total: $1,037.00 |
| 1 | 50 | $35.36 | Total: $1,768.00 |
| 1 | 100 | $30.60 | Total: $3,060.00 |
Overview
MKI-1 (MASTL Kinase Inhibitor-1) is an inhibitor of MASTL (microtubule-associated serinethreonine kinase-like, IC50= 9.9 ?M). MKI-1 exerts radiosensitizer and antitumor activities through PP2A activation in breast cancer.
Chemical Properties
| Molecular Formula | C18H14N4O |
| Molecular Weight | 302.33 |
| CAS Numbers | 1190277-80-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C(Nc1nc2ccccc2[nH]1)c1cccc(c1)-n1cccc1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Ah-Young Kim, et al. MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast cancer. Front Oncol. 2020 Sep 29;10 571601.